{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:10:22Z","timestamp":1794237022824,"version":"4.9.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG17786"],"award-info":[{"award-number":["IG17786"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG23117"],"award-info":[{"award-number":["IG23117"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jhep.2022.04.038","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T21:09:51Z","timestamp":1652821791000},"page":"849-864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["Metabolic reprogramming in cholangiocarcinoma"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-3535","authenticated-orcid":false,"given":"Chiara","family":"Raggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-6670","authenticated-orcid":false,"given":"Colin","family":"Rae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-1259","authenticated-orcid":false,"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-0878","authenticated-orcid":false,"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.04.038_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.04.038_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib4","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.3748\/wjg.14.3471","article-title":"Food-borne parasitic zoonosis: distribution of trichinosis in Thailand","volume":"14","author":"Kaewpitoon","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.04.038_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.actatropica.2003.01.001","article-title":"Opisthorchis viverrini and opisthorchiasis: a historical review and future perspective","volume":"88","author":"Upatham","year":"2003","journal-title":"Acta Trop"},{"key":"10.1016\/j.jhep.2022.04.038_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030688","article-title":"New and emerging systemic therapeutic options for advanced cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2022.04.038_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.04.038_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/1878-0261.12189","article-title":"Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition","volume":"12","author":"Pietrovito","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib10","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhep.2022.04.038_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2022.04.038_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","article-title":"Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition","volume":"537","author":"Sciacovelli","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.04.038_bib14","doi-asserted-by":"crossref","first-page":"e","DOI":"10.1017\/erm.2019.4","article-title":"Warburg and Krebs and related effects in cancer","volume":"21","author":"Unterlass","year":"2019","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.jhep.2022.04.038_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5483\/BMBRep.2014.47.3.273","article-title":"Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy","volume":"47","author":"Kee","year":"2014","journal-title":"BMB Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the Intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.04.038_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113466","article-title":"The Roles of Autophagy in Cancer","volume":"19","author":"Yun","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhep.2022.04.038_bib19","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2022.04.038_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2013.01.042","article-title":"Microenvironment and tumor cell plasticity: an easy way out","volume":"341","author":"Taddei","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2022.04.038_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010028","article-title":"Metabolic reprogramming of cancer cells during tumor progression and metastasis","volume":"11","author":"Ohshima","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.jhep.2022.04.038_bib22","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1021\/acs.biochem.0c00354","article-title":"Improving the treatment of acute lymphoblastic leukemia","volume":"59","author":"Radadiya","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.jhep.2022.04.038_bib23","doi-asserted-by":"crossref","first-page":"e26015","DOI":"10.1097\/MD.0000000000026015","article-title":"Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study","volume":"100","author":"Hwang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2022.04.038_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000000998","article-title":"Role of 18F-FDG PET\/CT imaging in intrahepatic cholangiocarcinoma","volume":"41","author":"Jiang","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jhep.2022.04.038_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13139-018-0542-9","article-title":"Inverse prognostic relationships of 18F-FDG PET\/CT metabolic parameters in patients with distal bile duct cancer undergoing curative surgery","volume":"52","author":"Yi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhep.2022.04.038_bib26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.dld.2015.03.017","article-title":"Relationship between 18-F-fluoro-deoxy-D-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma","volume":"47","author":"Suzuki","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2022.04.038_bib27","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.humpath.2014.03.008","article-title":"Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma","volume":"45","author":"Kubo","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2022.04.038_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-018-1475-x","article-title":"Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis","volume":"16","author":"Ikeno","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhep.2022.04.038_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2017.01.139","article-title":"Targeting hexokinase II as a possible therapy for cholangiocarcinoma","volume":"484","author":"Thamrongwaranggoon","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2022.04.038_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clinre.2019.06.008","article-title":"PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma","volume":"44","author":"Qian","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2022.04.038_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.27611","article-title":"Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer","volume":"119","author":"Dhar","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2022.04.038_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-015-0462-6","article-title":"PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma","volume":"14","author":"Yu","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2022.04.038_bib33","first-page":"503","article-title":"Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis","volume":"32","author":"Thonsri","year":"2017","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.jhep.2022.04.038_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1477-7819-12-78","article-title":"Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment","volume":"12","author":"Yu","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib35","doi-asserted-by":"crossref","first-page":"24136","DOI":"10.1038\/srep24136","article-title":"The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy","volume":"6","author":"Faloppi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.04.038_bib37","doi-asserted-by":"crossref","first-page":"18995","DOI":"10.1038\/srep18995","article-title":"High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation","volume":"6","author":"Saengboonmee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib38","doi-asserted-by":"crossref","first-page":"118548","DOI":"10.1016\/j.lfs.2020.118548","article-title":"NF-\u03baB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells","volume":"262","author":"Saengboonmee","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib39","doi-asserted-by":"crossref","first-page":"119114","DOI":"10.1016\/j.lfs.2021.119114","article-title":"High glucose upregulates FOXM1 expression via EGFR\/STAT3 dependent activation to promote progression of cholangiocarcinoma","volume":"271","author":"Detarya","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/cas.14719","article-title":"High glucose-ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8","volume":"112","author":"Thonsri","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib41","doi-asserted-by":"crossref","first-page":"109766","DOI":"10.1016\/j.biopha.2019.109766","article-title":"Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma","volume":"123","author":"Hong","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhep.2022.04.038_bib42","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/tox.23346","article-title":"Long noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa-miR-23b-3p\/KCND2 axis","volume":"36","author":"Lei","year":"2021","journal-title":"Environ Toxicol"},{"key":"10.1016\/j.jhep.2022.04.038_bib43","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/cam4.2089","article-title":"SIRT3 elicited an anti-Warburg effect through HIF1\u03b1\/PDK1\/PDHA1 to inhibit cholangiocarcinoma tumorigenesis","volume":"8","author":"Xu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2022.04.038_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060539","article-title":"Low VDAC1 expression is associated with an aggressive phenotype and reduced overall patient survival in cholangiocellular carcinoma","volume":"8","author":"Feichtinger","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2022.04.038_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bcp.2019.05.017","article-title":"UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals","volume":"166","author":"Yu","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2022.04.038_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12915-019-0671-3","article-title":"Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer","volume":"17","author":"Akella","year":"2019","journal-title":"BMC Biol"},{"key":"10.1016\/j.jhep.2022.04.038_bib47","doi-asserted-by":"crossref","first-page":"27853","DOI":"10.1038\/srep27853","article-title":"Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-\u03baB","volume":"6","author":"Phoomak","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib48","doi-asserted-by":"crossref","first-page":"43842","DOI":"10.1038\/srep43842","article-title":"High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation","volume":"7","author":"Phoomak","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib49","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/s41388-018-0366-1","article-title":"O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1","volume":"37","author":"Phoomak","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2022.04.038_bib50","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.002717","article-title":"High-mannose glycans are elevated during breast cancer progression","volume":"10","author":"de Leoz","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jhep.2022.04.038_bib51","doi-asserted-by":"crossref","first-page":"e0173712","DOI":"10.1371\/journal.pone.0173712","article-title":"Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS","volume":"12","author":"Qu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.04.038_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib53","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.28496","article-title":"FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling","volume":"63","author":"Guan","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib54","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1007\/s13277-016-5015-0","article-title":"Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents","volume":"37","author":"Samatiwat","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jhep.2022.04.038_bib55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3892\/ijo.2020.5158","article-title":"Serine, glycine and onecarbon metabolism in cancer (Review)","volume":"58","author":"Pan","year":"2021","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neo.2019.03.002","article-title":"The SIRT2\/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming","volume":"21","author":"Xu","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhep.2022.04.038_bib57","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2022.04.038_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2017.11.024","article-title":"Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas","volume":"90","author":"Delahousse","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2022.04.038_bib59","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2022.04.038_bib60","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3748\/wjg.v22.i6.2071","article-title":"Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice","volume":"22","author":"Ding","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.04.038_bib61","doi-asserted-by":"crossref","first-page":"18859","DOI":"10.1038\/s41598-019-55211-w","article-title":"Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation","volume":"9","author":"Fujiwara","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib63","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib64","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-018-0494-0","article-title":"PGC1\u03b1 promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2022.04.038_bib65","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41598-021-81172-0","article-title":"Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells","volume":"11","author":"Di Matteo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib66","doi-asserted-by":"crossref","first-page":"570516","DOI":"10.3389\/fonc.2020.570516","article-title":"Nuclear magnetic resonance-based metabolomic analysis of the anticancer effect of metformin treatment on cholangiocarcinoma cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep.26092","article-title":"Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk","volume":"57","author":"Chaiteerakij","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib68","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.18632\/oncotarget.3063","article-title":"Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2022.04.038_bib69","doi-asserted-by":"crossref","first-page":"587666","DOI":"10.3389\/fonc.2020.587666","article-title":"Metformin and biliary tract cancer in patients with type 2 diabetes","volume":"10","author":"Tseng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hep.27821","article-title":"Metformin does not improve survival of cholangiocarcinoma patients with diabetes","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.devcel.2020.06.018","article-title":"Cancer cells don\u2019t live alone: metabolic communication within tumor microenvironments","volume":"54","author":"Li","year":"2020","journal-title":"Dev Cell"},{"key":"10.1016\/j.jhep.2022.04.038_bib72","first-page":"10","article-title":"Tumor lymphatic interactions induce CXCR2-CXCL5 axis and alter cellular metabolism and lymphangiogenic pathways to promote cholangiocarcinoma","author":"Roy","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2022.04.038_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib74","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/hep.28508","article-title":"Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib75","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3892\/or.2014.3484","article-title":"Expression and roles of fatty acid synthase in hepatocellular carcinoma","volume":"32","author":"Hao","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32344","article-title":"Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids","author":"Ruiz de Gauna","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib77","doi-asserted-by":"crossref","first-page":"696961","DOI":"10.3389\/fphar.2021.696961","article-title":"Targeting fatty acid synthase modulates metabolic pathways and inhibits cholangiocarcinoma cell progression","volume":"12","author":"Tomacha","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2022.04.038_bib78","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3389\/fonc.2020.01025","article-title":"KDM5C represses FASN-mediated lipid metabolism to exert tumor suppressor activity in intrahepatic cholangiocarcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00795-019-00230-9","article-title":"Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location","volume":"53","author":"Nakagawa","year":"2020","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.jhep.2022.04.038_bib80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13046-017-0641-y","article-title":"Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4","volume":"36","author":"Nie","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030596","article-title":"Multifaceted aspects of metabolic plasticity in human cholangiocarcinoma: an overview of current perspectives","volume":"9","author":"Pastore","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2022.04.038_bib82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","article-title":"Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities","volume":"2","author":"Huang","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","article-title":"Molecular pathogenesis of cholangiocarcinoma","volume":"19","author":"Labib","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2022.04.038_bib84","doi-asserted-by":"crossref","first-page":"16492","DOI":"10.1073\/pnas.2002672117","article-title":"JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma","volume":"117","author":"Manieri","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2022.04.038_bib85","doi-asserted-by":"crossref","first-page":"501739","DOI":"10.1155\/2009\/501739","article-title":"Regulation of bile acid and cholesterol metabolism by PPARs","volume":"2009","author":"Li","year":"2009","journal-title":"PPAR Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0220001","article-title":"Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences","volume":"22","author":"Holden","year":"1999","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jhep.2022.04.038_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","article-title":"Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development","volume":"12","author":"Lozano","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081869","article-title":"Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?","volume":"20","author":"Baiocchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib89","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2022.04.038_bib90","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.27085","article-title":"Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib91","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib92","doi-asserted-by":"crossref","first-page":"39809","DOI":"10.18632\/oncotarget.9489","article-title":"Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer","volume":"7","author":"Miolo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2022.04.038_bib93","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.04.038_bib94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","article-title":"Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis","volume":"70","author":"Banales","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib95","doi-asserted-by":"crossref","first-page":"112598","DOI":"10.18632\/oncotarget.22607","article-title":"Reduced levels of N\u2019-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2022.04.038_bib96","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40170-021-00266-5","article-title":"Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma","volume":"9","author":"Padthaisong","year":"2021","journal-title":"Cancer Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib98","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neo.2019.10.004","article-title":"Glutamine deprivation counteracts hypoxia-induced chemoresistance","volume":"22","author":"Wappler","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhep.2022.04.038_bib99","doi-asserted-by":"crossref","first-page":"22830","DOI":"10.3390\/ijms160922830","article-title":"Targeting glutamine induces apoptosis: a cancer therapy approach","volume":"16","author":"Chen","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1152\/physrev.1990.70.1.43","article-title":"Role of amino acid transport and countertransport in nutrition and metabolism","volume":"70","author":"Christensen","year":"1990","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jhep.2022.04.038_bib101","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.cellsig.2014.04.002","article-title":"Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration","volume":"26","author":"Janpipatkul","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jhep.2022.04.038_bib102","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","article-title":"Metabolic rearrangements in primary liver cancers: cause and consequences","volume":"16","author":"Satriano","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib103","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/13543784.15.7.815","article-title":"Pegylated arginine deiminase: a novel anticancer enzyme agent","volume":"15","author":"Feun","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2022.04.038_bib104","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajpath.2010.10.023","article-title":"DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma","volume":"178","author":"Liu","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2022.04.038_bib105","doi-asserted-by":"crossref","first-page":"16294","DOI":"10.1038\/srep16294","article-title":"Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma","volume":"5","author":"Murakami","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031268","article-title":"Serotonin Pathway in Cancer","volume":"22","author":"Balakrishna","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib107","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1158\/0008-5472.CAN-08-2133","article-title":"Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth","volume":"68","author":"Alpini","year":"2008","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.04.038_bib108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.31310","article-title":"Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.04.038_bib110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1078-0432.CCR-08-1084","article-title":"The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma","volume":"15","author":"Chung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib111","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4149\/neo_2012_018","article-title":"Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma","volume":"59","author":"Wang","year":"2012","journal-title":"Neoplasma"},{"key":"10.1016\/j.jhep.2022.04.038_bib112","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and molecular effects of the mTOR inhibitor everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jhep.2022.04.038_bib113","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","article-title":"Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c","volume":"15","author":"Hagiwara","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib114","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","article-title":"Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice","volume":"67","author":"Zhang","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.04.038_bib116","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63645-0","article-title":"Identification of novel cellular targets in biliary tract cancers using global gene expression technology","volume":"163","author":"Hansel","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2022.04.038_bib117","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","article-title":"Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis","volume":"71","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib118","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3748\/wjg.v25.i31.4300","article-title":"Methionine adenosyltransferases in liver cancer","volume":"25","author":"Murray","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.04.038_bib119","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28541","article-title":"Deregulated methionine adenosyltransferase \u03b11, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(\u2021)","volume":"64","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0168-8278(00)80122-1","article-title":"Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma","volume":"33","author":"Avila","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib121","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","article-title":"Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer","volume":"155","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.04.038_bib122","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.28964","article-title":"Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells","volume":"65","author":"Fan","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.12.031","article-title":"Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma","author":"Raggi","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib124","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jhep.2016.08.012","article-title":"Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages","volume":"66","author":"Raggi","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2022.04.038_bib125","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/hep.27026","article-title":"Epigenetic reprogramming modulates malignant properties of human liver cancer","volume":"59","author":"Raggi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib126","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1038\/s41598-020-78539-0","article-title":"BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma","volume":"10","author":"Tamai","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.04.038_bib127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-021-00249-6","article-title":"Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models","volume":"9","author":"Thanee","year":"2021","journal-title":"Cancer Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib128","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/cas.12967","article-title":"CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: a target for cholangiocarcinoma treatment","volume":"107","author":"Thanee","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2022.04.038_bib129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Lin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.04.038_bib130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2022.04.038_bib131","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib132","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2022.04.038_bib133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jhep.2022.04.038_bib134","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163754","article-title":"Targeting as a new potential option for intrahepatic cholangiocarcinoma treatment-current state and future perspectives","volume":"25","author":"Crispo","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jhep.2022.04.038_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113310","article-title":"IDH signalling pathway in cholangiocarcinoma: from biological rationale to therapeutic targeting","volume":"12","author":"Salati","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2022.04.038_bib137","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acsmedchemlett.7b00342","article-title":"Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor","volume":"8","author":"Cho","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jhep.2022.04.038_bib138","article-title":"A phase 1 study of IDH305 in patients with IDH1","author":"DiNardo","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib139","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib140","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10637-021-01094-6","article-title":"A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors","volume":"39","author":"Azaro","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jhep.2022.04.038_bib141","doi-asserted-by":"crossref","first-page":"e014961","DOI":"10.1136\/bmjopen-2016-014961","article-title":"Study protocol of a phase IB\/II clinical trial of metformin and chloroquine in patients with","volume":"7","author":"Molenaar","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2022.04.038_bib142","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1042\/BST20110602","article-title":"Sphingosine 1-phosphate signalling in cancer","volume":"40","author":"Pyne","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.jhep.2022.04.038_bib143","doi-asserted-by":"crossref","first-page":"20080","DOI":"10.18632\/oncotarget.7914","article-title":"Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells","volume":"7","author":"Ding","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2022.04.038_bib144","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","article-title":"A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors","volume":"23","author":"Britten","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2049-3002-2-4","article-title":"A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process","volume":"2","author":"Stuart","year":"2014","journal-title":"Cancer Metab"},{"key":"10.1016\/j.jhep.2022.04.038_bib146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-020-01579-x","article-title":"CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling","volume":"39","author":"Gao","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.04.038_bib147","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial","volume":"18","author":"Alistar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib148","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41416-018-0021-1","article-title":"Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study","volume":"118","author":"Lau","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2022.04.038_bib149","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/annonc\/mdu175","article-title":"Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study","volume":"25","author":"Buzzoni","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2022.04.038_bib150","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/carcin\/bgq131","article-title":"Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer","volume":"31","author":"Igal","year":"2010","journal-title":"Carcinogenesis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822003142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:11Z","timestamp":1759175291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822003142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":150,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0168827822003142"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic reprogramming in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}